ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica ...
R-MPV plus Imbruvica achieved a 97% complete response rate in newly diagnosed PCNSL patients, with a 100% overall response rate and no refractory cases. The two-year progression-free survival rate was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback